Tom Baker Cancer Center/Alberta Health Services
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bahlis, Nizar
NCT03421132: Multiple Myeloma Molecular Monitoring Study

Active, not recruiting
N/A
96
Canada
Horizon Health Network
Multiple Myeloma
12/24
03/26
Gasparetto, Cristina
NCT02452697: Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

Active, not recruiting
2
36
US
NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
Cristina Gasparetto, Agilent Technologies, Inc.
Myeloid Malignancies, Lymphoid Malignancies
07/22
10/24
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Recruiting
1
125
Europe, Canada, US
Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide
K36 Therapeutics, Inc.
Multiple Myeloma, Myeloma, Myeloma Multiple
12/25
06/26
CaMMouflage, NCT05722418: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1
50
US
CB-011, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
02/25
02/27
NCT05397132: Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Recruiting
N/A
50
US
Blood draw
Duke University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Hematologic Malignancy
11/25
11/25

Download Options